MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,563 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,083 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of Supernus Pharmaceuticals worth $1,033,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after acquiring an additional 28,517 shares during the period. American Century Companies Inc. increased its position in Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock valued at $41,248,000 after acquiring an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock valued at $27,242,000 after acquiring an additional 40,968 shares during the period. Finally, Northern Trust Corp lifted its holdings in Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company’s stock valued at $25,933,000 after acquiring an additional 110,867 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SUPN. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 16th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 0.2%

NASDAQ SUPN opened at $32.10 on Monday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The company has a market capitalization of $1.80 billion, a P/E ratio of 30.00 and a beta of 0.74. The stock’s 50-day moving average price is $31.98 and its 200-day moving average price is $34.74.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.